<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30632023</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>07</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7217</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>174</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Breast cancer research and treatment</Title>
          <ISOAbbreviation>Breast Cancer Res Treat</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.</ArticleTitle>
        <Pagination>
          <StartPage>719</StartPage>
          <EndPage>729</EndPage>
          <MedlinePgn>719-729</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-018-05125-4</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P &lt; 0.001]. Herein, we report results overall and by subgroups with extended follow-up.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P &lt; 0.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib-letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients' quality of life was maintained.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rugo</LastName>
            <ForeName>H S</ForeName>
            <Initials>HS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine (Hematology/Oncology), University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, 2nd Floor, San Francisco, CA, 94115, USA. hope.rugo@ucsf.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Finn</LastName>
            <ForeName>R S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diéras</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Institut Curie, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre Eugène Marquis, Rennes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ettl</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lipatov</LastName>
            <ForeName>O</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Republican Clinical Oncology Dispensary, State Budget Medical Institution, Ufa, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joy</LastName>
            <ForeName>A A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harbeck</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castrellon</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Breast Cancer Center, Memorial Cancer Institute, Hollywood, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iyer</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Patient and Health Impact, Pfizer Inc, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>D R</ForeName>
            <Initials>DR</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Statistics, Pfizer Inc, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mori</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Global Product Development, Clinical, Pfizer S.r.l, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gauthier</LastName>
            <ForeName>E R</ForeName>
            <Initials>ER</Initials>
            <AffiliationInfo>
              <Affiliation>Global Product Development, Clinical, Pfizer Inc, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bartlett</LastName>
            <ForeName>C Huang</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Global Product Development, Clinical, Pfizer Inc, Collegeville, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gelmon</LastName>
            <ForeName>K A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Slamon</LastName>
            <ForeName>D J</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>01</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Breast Cancer Res Treat</MedlineTA>
        <NlmUniqueID>8111104</NlmUniqueID>
        <ISSNLinking>0167-6806</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G9ZF61LE7G</RegistryNumber>
          <NameOfSubstance UI="C500026">palbociclib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Breast cancer</Keyword>
        <Keyword MajorTopicYN="Y">Cyclin-dependent kinase inhibitor</Keyword>
        <Keyword MajorTopicYN="Y">ER+</Keyword>
        <Keyword MajorTopicYN="Y">HER2−</Keyword>
        <Keyword MajorTopicYN="Y">Letrozole</Keyword>
        <Keyword MajorTopicYN="Y">Palbociclib</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICT OF INTEREST: HSR’s institution received research funding from Plexxikon, Macrogenics, OBI Pharma, Eisai, Pfizer, Novartis, Eli Lilly, Roche, and Merck. RSF received consulting fees from Pfizer, Bayer, Novartis, Bristol-Myers Squibb, Merck, Eli Lilly, Eisai, and Roche/Genentech as well as other research funding from Pfizer. VD received consulting fees from Genentech, Eli Lilly, Pfizer, Astellas, AbbVie, Novartis Pharma KK, Daichy, Tesaro, NSD, Seattle Genetics, and Roche-Peru, as well as speakers bureau fees from Pfizer, Novartis Pharma KK, and Roche-Peru. JE received consulting fees from Eli Lilly, Novartis, Pfizer, Roche, and Eisai, performed contracted research for Celgene, and received honoraria from Eli Lilly, Novartis, Pfizer, Roche, TEVA, and Pierre Fabre. AAJ received consulting fees from Amgen, AbbVie, AstraZeneca, BMS, Eli Lilly, Pfizer, Novartis, and Roche. NH received consulting fees for Eli Lilly, Novartis, and Pfizer. AC received consulting/advisory fees from Agendia. KAG received consulting/advisory fees from Pfizer, Novartis, AstraZeneca, NanoString Technologies, Merck, Eli Lilly, Genomic Health, Roche, Seattle Genetics, and Mylan. DJS received consulting fees from Pfizer, Eli Lilly, and Novartis, performed contracted research for Pfizer and Novartis, is a Pfizer stockholder, received travel accommodation/expenses from Pfizer and BioMarin, and has a leadership role with BioMarin. CHB, ERG, SI, DRL, and AM are employees of and own stock in Pfizer. OL has nothing to disclose. ETHICAL APPROVAL: This trial complies with the current laws of the countries in which it was performed.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30632023</ArticleId>
        <ArticleId IdType="pmc">PMC6438948</ArticleId>
        <ArticleId IdType="doi">10.1007/s10549-018-05125-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s10549-018-05125-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) Breast. 2017;31:244–259. doi: 10.1016/j.breast.2016.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.breast.2016.10.001</ArticleId>
            <ArticleId IdType="pubmed">27927580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rugo H, Rumble B, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield LA, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian J, M RS, Muss HB, Burstein HJ. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 2016;34:3069–3103. doi: 10.1200/JCO.2016.67.1487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.67.1487</ArticleId>
            <ArticleId IdType="pubmed">27217461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Comprehensive Cancer Network (2017) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast cancer. Version 4.2017 https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed Feb 12 2018</Citation>
        </Reference>
        <Reference>
          <Citation>Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936. doi: 10.1056/NEJMoa1607303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1607303</ArticleId>
            <ArticleId IdType="pubmed">27959613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>IBRANCE® (palbociclib)   Full prescribing information. New York: Pfizer Inc; 2018. </Citation>
        </Reference>
        <Reference>
          <Citation>Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974–986. doi: 10.1200/JCO.1997.15.3.974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1997.15.3.974</ArticleId>
            <ArticleId IdType="pubmed">9060536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>EuroQoL Group  EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208. doi: 10.1016/0168-8510(90)90421-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0168-8510(90)90421-9</ArticleId>
            <ArticleId IdType="pubmed">10109801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, Cella D, Cameron D, Amonkar MM, Segreti A, Stein S, Walker M, Geyer CE. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009;117:577–589. doi: 10.1007/s10549-009-0310-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-009-0310-8</ArticleId>
            <ArticleId IdType="pubmed">19153829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonetti M, Zahrieh D, Cole BF, Gelber RD. A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data. Stat Med. 2009;28:1255–1268. doi: 10.1002/sim.3524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sim.3524</ArticleId>
            <ArticleId IdType="pmc">PMC2843827</ArticleId>
            <ArticleId IdType="pubmed">19170050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35. doi: 10.1016/S1470-2045(14)71159-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)71159-3</ArticleId>
            <ArticleId IdType="pubmed">25524798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M, Group PS. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219. doi: 10.1056/NEJMoa1505270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1505270</ArticleId>
            <ArticleId IdType="pubmed">26030518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O’Shaughnessy J. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–1748. doi: 10.1056/NEJMoa1609709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1609709</ArticleId>
            <ArticleId IdType="pubmed">27717303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribociclib extends survival in HR + breast cancer  Cancer Discov. 2018;8:OF5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29229752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sledge GW, Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875–2884. doi: 10.1200/JCO.2017.73.7585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.73.7585</ArticleId>
            <ArticleId IdType="pubmed">28580882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–3646. doi: 10.1200/JCO.2017.75.6155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.75.6155</ArticleId>
            <ArticleId IdType="pubmed">28968163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rugo HS, Dieras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CH, Iyer S, Johnston S, Ettl J, Harbeck N. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29:888–894. doi: 10.1093/annonc/mdy012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy012</ArticleId>
            <ArticleId IdType="pmc">PMC5913649</ArticleId>
            <ArticleId IdType="pubmed">29360932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung K-L, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ. Fulvestrant 500mg versus anastrozole 1mg for hormone receptor-positive advanced breast cancer (FALCON): an International, Randomised, Double-blind, Phase 3 Trial. Lancet. 2016;388:2997–3005. doi: 10.1016/S0140-6736(16)32389-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)32389-3</ArticleId>
            <ArticleId IdType="pubmed">27908454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:3307–3329. doi: 10.1200/JCO.2014.56.7479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2014.56.7479</ArticleId>
            <ArticleId IdType="pmc">PMC6076042</ArticleId>
            <ArticleId IdType="pubmed">25185096</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
